Login to Your Account



All smiles for United's Unituxin in pediatric high-risk neuroblastoma

By Marie Powers
Staff Writer

Tuesday, March 10, 2015

United Therapeutics Corp. punched a golden ticket with Unituxin, which the FDA green-lighted to treat children with high-risk neuroblastoma, along with the award of a rare pediatric disease priority review voucher.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription